Evidence mapPaperPMID 33299530Full record

ArticleOxidative medicine and cellular longevity2020

Paricalcitol Attenuates Contrast-Induced Acute Kidney Injury by Regulating Mitophagy and Senescence.

Eunjin Bae, Jin Hyun Kim, Myeong Hee Jung, Si Jung Jang, Tae Won Lee, Sehyun Jung, Seunghye Lee, Ha Nee Jang, Se-Ho Chang, Dong Jun Park

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 38 citations in OpenAlex.

  1. Molecules (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. High-mobility group box 1 in acute kidney injury.Frontiers in pharmacology · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Research progress on animal models of contrast-induced acute kidney injury.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Tolvaptan Improves Contrast-Induced Acute Kidney Injury.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Eunjin Bae *Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
Jin Hyun Kim *Institute of Health Science, College of Medicine, Gyeongsang National University, Jinju, Republic of Korea.
Myeong Hee JungBiomedical Research Institute, Gyeongsang National University Hospital, Jinju, Republic of Korea.
Si Jung JangBiomedical Research Institute, Gyeongsang National University Hospital, Jinju, Republic of Korea.
Tae Won LeeDepartment of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
Sehyun JungDepartment of Internal Medicine, Gyeongsang National University Hospital, Jinju, Republic of Korea.
Seunghye LeeDepartment of Internal Medicine, Gyeongsang National University Hospital, Jinju, Republic of Korea.
Ha Nee JangDepartment of Internal Medicine, Gyeongsang National University Hospital, Jinju, Republic of Korea.
Se-Ho ChangDepartment of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Republic of Korea.
Dong Jun ParkDepartment of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.ORCID https://orcid.org/0000-0001-5233-537X
Gyeongsang National University Hospital · KRChangwon National University · KRGyeongsang National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Contrast-induced acute kidney injury (CI-AKI) is the third most common cause of hospital-acquired renal failure, with an incidence of 11%. However, the disease mechanism remains unclear, and no effective treatment is available. Paricalcitol has been reported to be effective in animal models of kidney injury. We hypothesized that paricalcitol could play a renoprotective role against CI-AKI. Rats were divided into control, paricalcitol, contrast, and paricalcitol-plus-contrast groups. We used a previously published protocol to produce CI-AKI. Paricalcitol (0.3

Indexed as

Acute Kidney InjuryAnimalsContrast MediaEpithelial CellsErgocalciferolsKidneyKidney TubulesMaleMitochondriaMitophagyRatsUbiquitin-Protein LigasesContrast MediaErgocalciferolsparicalcitolparkin proteinUbiquitin-Protein Ligases

Identifiers

PMID33299530
PMCPMC7704155
OpenAlexW3106930514

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.